Archive summary Clinical
Topic
Anxiety
Every article tagged “Anxiety”, newest first.
232 articles · page 3 of 6 · Jan 20, 2026 – Mar 11, 2026
Archive summary Clinical
When mood swings signal something more serious
The shift can be subtle at first. Your motivated teen who once enjoyed staying late at practice now wants to quit her favorite sport. Grades start slipping. You might…
Archive summary Clinical
Tonix Pharmaceuticals Presented Data On TONMYATM In Treating Patients With Fibromyalgia At The 2026 AAPM Painconnect Annual Meeting
TONMYA (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults, was commercially launched in November 2025 Treatment with TONMYA ...
Archive summary Clinical
VTGN DEADLINE NOTICE: ROSEN, A TOP RANKED LAW FIRM, Encourages Vistagen Therapeutics, Inc. ...
Archive summary Clinical
AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business ...
Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression remains on track for Q2 2026 following successful End‐of‐Phase 2 meeting with the U.S.…
Archive summary Clinical
Tonix Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Studies of TONMYATM and Prototype Formulations in the Journal Clinical Pharmacology in Drug Development
Commercially launched in the U.S. in November 2025, TONMYA (cyclobenzaprine HCl sublingual tablets) for long-term daily dosing at bedtime is the first new FDA-approved…
Archive summary Clinical
VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds ...
NEW YORK, March 05, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Vistagen Therapeutics, Inc. (“Vistagen” or…
Archive summary Clinical
VTGN DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. ...
Archive summary Clinical
Psychologists are finding more ways to use virtual reality in therapy
Psychologists are expanding the use of virtual reality in therapeutic settings, developing interventions that help patients develop stronger connections to their future…
Archive summary Clinical
From Rett and Pitt-Hopkins to ALS: 5 Rare Diseases UC San Diego Researchers are Tackling in the Lab
This Rare Disease Day (February 28, 2026), read on to learn more about five orphan conditions, the people they affect and the UC San Diego Sanford Stem Cell Institute…
Archive summary Clinical
U.S. FDA Grants Reunion Neuroscience’s Luvesilocin (RE104) Breakthrough Therapy Designation Status
Breakthrough Therapy Designation Based on Positive RECONNECT Phase 2 Clinical Data --
Archive summary Clinical
As More Americans Embrace Anxiety Treatment, MAHA Derides Medications
Robert F. Kennedy Jr. has criticized the broadening use of anxiety medications, claiming they’re harmful. Doctors and researchers say the MAHA movement is…
Archive summary Clinical
As more Americans embrace anxiety treatment, RFK Jr. derides medications
Robert F. Kennedy Jr. has criticized the broadening use of anxiety medications, but doctors and researchers say the MAHA movement is misrepresenting drugs that have been…
Archive summary Clinical
Contact The Gross Law Firm By March 16, 2026 Deadline To Join Class Action Against Vistagen Therapeutics, Inc.(VTGN)
NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Vistagen Therapeutics, Inc. (NASDAQ: VTGN). ...
Archive summary Clinical
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Vistagen Therapeutics, Inc. Investors to Secure ...
Archive summary Clinical
Lenire Shows Consistent Positive Results For U.S. Tinnitus Patients In 2Nd Peer-Reviewed Real-World Study
81.8% of patients with bothersome tinnitus treated with Lenire at New York Hearing Doctors reported significant improvement in a real-world clinical setting.1,2 Patients…
Archive summary Clinical
VTGN SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics (VTGN) Investors ...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered In Vistagen To Contact Him Directly To Discuss Their Options
Archive summary Clinical
VTGN Investors with Large Losses Should Contact Robbins LLP for Information About Leading the ...
SAN DIEGO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of all investors who purchased or otherwise acquired…
Archive summary Clinical
‘Longevity fixation syndrome’: the allure of eternal youth
Obsession with beating biological clock identified as damaging new addiction
Archive summary Clinical
Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb 12, 2026--
Archive summary Clinical
Vanda Pharmaceuticals Q4 Earnings Call Highlights
Vanda Pharmaceuticals (NASDAQ:VNDA) highlighted strong growth for its lead product Fanapt and detailed several late-stage regulatory and clinical milestones during its…
Archive summary Clinical
What is EMDR therapy, and who can it help?
EMDR therapy is best known for helping people recover from trauma, but it may also benefit those with anxiety, depression, and other mental health conditions.
Archive summary Clinical
6 Psychiatry Headlines You Missed in January 2026
Archive summary Clinical
Bragar Eagel & Squire, P.C. Urges Vistagen Therapeutics, Inc. Stockholders to Contact the ...
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Vistagen (VTGN) To Contact Him Directly To Discuss Their Options
Archive summary Clinical
Guideline-based treatment linked to better outcomes for kids with anxiety and depression
A new Yale study finds that adolescents with anxiety or depression fair better when doctors follow FDA approvals or professional treatment guidelines rather than…
Archive summary Clinical
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure ...
Archive summary Clinical
Addex Announces Publication Of Preclinical Data Supporting Potential Of Mglu7 Negative Allosteric Modulators To Transform Anxiety And Fear-Related Disorder Treatment
Data published in Molecular Psychiatry Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, February 3, 2026 - Addex Therapeutics (SIX: ADXN ...
Archive summary Clinical
From Croatia to MAHA: How an unapproved drug became the next hot peptide
BPC-157 hasn't been approved by the FDA. But that hasn't stopped this buzzy drug from gaining traction – and attention from MAHA.
Archive summary Clinical
Global Sleep Disorder Market Report 2026 Business Expansion, Key Growth Drivers, And Trends Through 2030
EINPresswire/ -- Understanding the growing importance of sleep health reveals why the sleep disorder market is expanding so rapidly. With an increasing number of people…
Archive summary Clinical
Psychosocial correlates of depression and anxiety among treatment-seeking individuals with opioid dependence: a cross-sectional study
A cross-sectional study of treatment-seeking individuals with opioid dependence in India reveals significant comorbidity between depression and anxiety, with…
Archive summary Clinical
A Guide to Proven Anxiety Treatment Options for 2025
Anxiety is one of the most treatable mental health conditions, though clinical anxiety disorder emerges when worry becomes excessive, difficult to control, and…
Archive summary Clinical
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Vistagen Therapeutics, Inc. Investors to Secure ...
Archive summary Clinical
Incannex Healthcare Announces Formation Of Clinical Advisory Board For PSX-001 Program
Strengthens clinical and regulatory guidance as PSX-001 advances to its next phase of developmentMELBOURNE, Australia and NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) ...
Archive summary Clinical
Lumateperone Shows Broad Symptom Benefit for MDD, With Michael E. Thase, MD
Adjunctive lumateperone 42 mg has demonstrated broad symptom improvement for patients with treatment-resistant major depressive disorder (MDD), according to analyses of…
Archive summary Clinical
Using AI for advice or other personal reasons linked to depression and anxiety
People who interact with chatbots for emotional support or other personal reasons are more likely to report symptoms of depression or anxiety, a new study finds. The…
Archive summary Clinical
Aytu BioPharma Recaps Investor Day Held on January 20, 2026
DENVER, CO / ACCESS Newswire / January 20, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative…
Archive summary Clinical
High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026
Market Analysis by covering: CorMedix Inc, ATAI Beckley Inc, Evommune Inc. Read 's Market Analysis on Investing.com
Archive summary Clinical
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure ...
Archive summary Clinical
VTGN Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the ...
SAN DIEGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of all investors who purchased or otherwise acquired…
Archive summary Clinical
Medical marijuana’s pain promise is under fire — again
The scientific review comes as Americans are increasingly turning to the plant to cope with chronic pain, sleep difficulties, anxiety and a wide range of other health…